title: Impact of patient financial incentives on participation and outcomes in a statin pill-splitting program.
abstract: OBJECTIVE
  To examine willingness to participate in a pill-splitting program and the impact of pill splitting on patients' adherence and lipid control.
  
  
  METHODS
  Nested randomized trial.
  
  
  METHODS
  A total of 200 patients who used statins and were candidates for a pill-splitting regimen were identified from a large university-based health plan. Sixty-three percent of study participants were female, 41% were nonwhite, and 94% had at least some college education. Patients were surveyed regarding their willingness to split pills, and 111 consented to participate in a 6-month trial in which half were randomized to receive a financial incentive to split pills: a 50% reduction in their per-refill copayment. Data on patients' statin refills and lipid control were obtained from billing and medical records.
  
  
  RESULTS
  Compared with patients unwilling to participate in the program, those agreeing to split pills were more likely to be female and white. After 6 months, most patients in the trial (89%) were willing to continue pill splitting for a 50% copayment reduction. Patients reported few problems with pill splitting and had no noticeable change in their adherence. The financial-incentive group and the control group did not differ significantly with respect to their low-density lipoprotein cholesterol levels after pill splitting: -2.0 mg/dL and -1.2 mg/dL, respectively.
  
  
  CONCLUSIONS
  Most patients indicated that at least a 50% copayment reduction would be required to enroll in a pill-splitting program after the study ended. However, in this relatively educated population, financial incentives did not influence patients' adherence, satisfaction, or health outcomes.
authors.affiliation: College of Pharmacy, University of Michigan, and the University of Michigan Hospitals and Health Centers, Ann Arbor, MI, USA. haemi@umich.edu
authors.forename: Hae Mi
authors.initials: HM
authors.lastname: Choe
authors.forename: James G
authors.initials: JG
authors.lastname: Stevenson
authors.forename: Daniel S
authors.initials: DS
authors.lastname: Streetman
authors.forename: Michele
authors.initials: M
authors.lastname: Heisler
authors.forename: Connie J
authors.initials: CJ
authors.lastname: Sandiford
authors.forename: John D
authors.initials: JD
authors.lastname: Piette
mesh_terms: D017046:Cost Savings / Q000379:methods; D003657:Decision Making; D011307:Drug Prescriptions / Q000191:economics*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D006937:Hypercholesterolemia / Q000188:drug therapy*; D008297:Male; D008329:Managed Care Programs / Q000191:economics*; D008824:Michigan; D008875:Middle Aged; D010043:Outcome and Process Assessment, Health Care; D010349:Patient Compliance; D010358:Patient Participation / Q000191:economics*; D017060:Patient Satisfaction; D012052:Reimbursement, Incentive; D012646:Self Administration / Q000379:methods; D013607:Tablets
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D013607:Tablets